D.E. Shaw & Co
FATE icon

D.E. Shaw & Co’s Fate Therapeutics FATE Stock Holding History

D.E. Shaw & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-433,192
Closed -$342K – 4453
2025
Q1 		$342K Sell
433,192
-1,103,441
-72% -$1.35M ﹤0.01% 3704
2024
Q4 		$2.54M Sell
1,536,633
-1,841,017
-55% -$4.64M ﹤0.01% 2541
2024
Q3 		$11.8M Sell
3,377,650
-700,272
-17% -$2.72M 0.01% 1308
2024
Q2 		$13.4M Buy
4,077,922
+1,346,956
+49% +$5.9M 0.01% 1153
2024
Q1 		$20M Sell
2,730,966
-851,013
-24% -$5.27M 0.02% 922
2023
Q4 		$13.4M Sell
3,581,979
-1,129,685
-24% -$2.67M 0.01% 1178
2023
Q3 		$9.99M Buy
4,711,664
+112,225
+2% +$372K 0.01% 1284
2023
Q2 		$21.9M Buy
4,599,439
+1,634,197
+55% +$9.02M 0.02% 814
2023
Q1 		$16.9M Buy
2,965,242
+2,707,319
+1,050% +$16.3M 0.02% 998
2022
Q4 		$2.6M Buy
+257,923
New +$4.84M ﹤0.01% 2706
2021
Q4 		– Sell
-17,821
Closed -$1.06M – 5492
2021
Q3 		$1.06M Sell
17,821
-65,727
-79% -$5.16M ﹤0.01% 3560
2021
Q2 		$7.25M Sell
83,548
-222,690
-73% -$17.9M 0.01% 1747
2021
Q1 		$25.2M Sell
306,238
-89,919
-23% -$8.62M 0.02% 805
2020
Q4 		$36M Sell
396,157
-130,170
-25% -$8.08M 0.03% 645
2020
Q3 		$21M Buy
526,327
+75,367
+17% +$2.63M 0.02% 803
2020
Q2 		$15.5M Buy
450,960
+29,759
+7% +$887K 0.02% 923
2020
Q1 		$9.36M Buy
421,201
+314,949
+296% +$7.96M 0.01% 1036
2019
Q4 		$2.08M Buy
+106,252
New +$1.69M ﹤0.01% 2431
2019
Q3 		– Sell
-13,322
Closed -$270K – 3871
2019
Q2 		$270K Buy
+13,322
New +$240K ﹤0.01% 3355
2018
Q2 		– Sell
-36,796
Closed -$359K – 3745
2018
Q1 		$359K Buy
+36,796
New +$352K ﹤0.01% 3054

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's FATE Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 433,192 shares — an estimated $342K sold.

D.E. Shaw & Co first reported a position in FATE in Q1 2018 and held it in 20 quarters. The position peaked at $36M in Q4 2020. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 433,192 Fate Therapeutics shares in Q2 2025, an estimated $342K.
  • D.E. Shaw & Co first reported a position in Fate Therapeutics in Q1 2018 and held it in 20 quarters.
  • D.E. Shaw & Co's Fate Therapeutics position peaked at $36M in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.